BIOSCRIP, INC. (NASDAQ:BIOS) Files An 8-K Regulation FD Disclosure

BIOSCRIP, INC. (NASDAQ:BIOS) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01. Regulation FD Disclosure.

On December 14, 2016, BioScrip, Inc. (the Company), in connection
with the Companys intention to seek an amendment (the Amendment)
of the Credit Agreement, dated July 31, 2013, as amended (the
Credit Agreement), will make a presentation to its lenders under
the Credit Agreement, a copy of which is furnished herewith as
Exhibit 99.1.

The Company issued a press release regarding the proposed
Amendment and providing a business update. A copy of the press
release is furnished herewith as Exhibit 99.2.

The information in this Item 7.01, including Exhibit 99.1 and
Exhibit 99.2, is being furnished and shall not be deemed filed
for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that
Section. The information in this Item 7.01, including Exhibit
99.1 and Exhibit 99.2, shall not be incorporated by reference
into any registration statement or other document to the
Securities Act of 1933, as amended. The Company undertakes no
duty or obligation to publicly update or revise the information
contained in this Current Report and cautions that the
information included in this Current Report under Item 7.01,
including Exhibit 99.1 and Exhibit 99.2, is current only as of
December 14, 2016 and may change thereafter. The furnishing of
the information in this report is not intended to, and does not,
constitute a determination or admission by the Company that the
information in this report is material or complete, or that
investors should consider this information before making an
investment decision with respect to any security of the Company.

Forward-Looking Statements

This current report includes statements that may constitute
forward-looking statements, that involve substantial risks and
uncertainties. These statements are made to the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. You can identify these statements by the fact that they do
not relate strictly to historical or current facts. In some
cases, forward-looking statements can be identified by words such
as may, should, could, anticipate, estimate, expect, project,
outlook, aim, intend, plan, believe, predict, potential, continue
or comparable terms. Because such statements inherently involve
risks and uncertainties, actual future results may differ
materially from those expressed or implied by such
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those in the forward-looking
statements as a result of various factors. Important factors that
could cause or contribute to such differences include but are not
limited to risks associated with: the Companys ability to
integrate the acquisition of Home Solutions, the Companys ability
to grow its core Infusion revenues, the Companys ability to
continue to experience positive results from its financial
improvement plan to reduce operating costs; the Companys ability
to consummate the Amendment and to comply with the covenants in
its debt agreements; the success of the Companys initiatives to
mitigate the impact of the Cures Act on its business; reductions
in federal, state and commercial reimbursement for the Companys
products and services; increased government regulation related to
the health care and insurance industries; as well as the risks
described in the Companys periodic filings with the Securities
and Exchange Commission. The Company does not undertake any duty
to update these forward-looking statements after the date hereof,
even though the Companys situation may change in the future. All
of the forward-looking statements in this report are qualified by
these cautionary statements.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description
99.1 Lender presentation, dated December 14, 2016.
99.2 Press release issued by the Company, dated December 14, 2016.


About BIOSCRIP, INC. (NASDAQ:BIOS)

BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

BIOSCRIP, INC. (NASDAQ:BIOS) Recent Trading Information

BIOSCRIP, INC. (NASDAQ:BIOS) closed its last trading session 00.00 at 1.12 with 777,417 shares trading hands.

An ad to help with our costs